MA37610A1 - Formulations de testostérone proliposomales - Google Patents

Formulations de testostérone proliposomales

Info

Publication number
MA37610A1
MA37610A1 MA37610A MA37610A MA37610A1 MA 37610 A1 MA37610 A1 MA 37610A1 MA 37610 A MA37610 A MA 37610A MA 37610 A MA37610 A MA 37610A MA 37610 A1 MA37610 A1 MA 37610A1
Authority
MA
Morocco
Prior art keywords
testosterone
lipid particle
testosterone formulations
proliposomal testosterone
proliposomal
Prior art date
Application number
MA37610A
Other languages
Arabic (ar)
English (en)
Other versions
MA37610B1 (fr
Inventor
Guru V Betageri
Ramachandran Thirucote
Veeran Gowda Kadajji
Original Assignee
Univ Western Health Sciences
Tesorx Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49551459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37610(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Western Health Sciences, Tesorx Pharma Llc filed Critical Univ Western Health Sciences
Publication of MA37610A1 publication Critical patent/MA37610A1/fr
Publication of MA37610B1 publication Critical patent/MA37610B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)

Abstract

La présente invention concerne de nouvelles formulations de testostérone dans lesquelles la testostérone est incorporée dans un système de phospholipide/cholestérol pour produire une dispersion de poudre proliposomale. Les dispersions de poudre proliposomales de l'invention peuvent être formulées avec des excipients pharmaceutiquement acceptables pour former des compositions pharmaceutiques. Les formes pharmaceutiques orales à enrobage entérique sont décrites ainsi que des procédés de traitement pour thérapie de remplacement de testostérone..
MA37610A 2012-05-09 2013-05-09 Formulations de testostérone proliposomales MA37610B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644996P 2012-05-09 2012-05-09
PCT/US2013/040325 WO2013170012A2 (fr) 2012-05-09 2013-05-09 Formulations de testostérone proliposomales

Publications (2)

Publication Number Publication Date
MA37610A1 true MA37610A1 (fr) 2016-07-29
MA37610B1 MA37610B1 (fr) 2017-07-31

Family

ID=49551459

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37610A MA37610B1 (fr) 2012-05-09 2013-05-09 Formulations de testostérone proliposomales

Country Status (32)

Country Link
US (5) US8957053B2 (fr)
EP (1) EP2846781B1 (fr)
JP (3) JP6055088B2 (fr)
KR (1) KR20150032939A (fr)
CN (2) CN104780914B (fr)
AP (1) AP2014008099A0 (fr)
AR (1) AR091006A1 (fr)
AU (2) AU2013259509B2 (fr)
BR (1) BR112014027942A2 (fr)
CA (1) CA2872779A1 (fr)
CL (1) CL2014003034A1 (fr)
CO (1) CO7240373A2 (fr)
CR (1) CR20140561A (fr)
DO (1) DOP2015000026A (fr)
EA (2) EA201791738A1 (fr)
EC (1) ECSP14030572A (fr)
GE (1) GEP201706754B (fr)
HK (3) HK1210409A1 (fr)
IL (1) IL235464B (fr)
IN (1) IN2014DN10383A (fr)
MA (1) MA37610B1 (fr)
MX (1) MX367123B (fr)
MY (1) MY175305A (fr)
NZ (2) NZ702634A (fr)
PE (1) PE20150203A1 (fr)
PH (1) PH12014502498A1 (fr)
SG (2) SG10201702240TA (fr)
TN (1) TN2014000467A1 (fr)
TW (2) TWI664982B (fr)
UA (1) UA115058C2 (fr)
WO (1) WO2013170012A2 (fr)
ZA (2) ZA201408996B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213440B2 (en) 2014-08-20 2019-02-26 Professional Compounding Centers Of America (Pcca) Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor
KR101682821B1 (ko) 2015-07-21 2016-12-06 서울대학교산학협력단 프로리포솜 제조방법
EA038653B1 (ru) * 2016-01-07 2021-09-29 Вестерн Юниверсити Оф Хелт Сайенсиз Составы для лечения рака мочевого пузыря
US20190248830A1 (en) * 2016-01-08 2019-08-15 Western University Of Health Sciences Proliposomal testosterone undecanoate formulations
KR102574139B1 (ko) 2016-07-07 2023-09-05 삼성전자주식회사 무선 충전 모드를 변경하는 장치 및 방법
BR112019009616A2 (pt) * 2016-11-11 2019-08-13 Western University Of Health Sciences métodos de tratamento de carcinomas uroteliais do trato superior
WO2019096833A1 (fr) 2017-11-17 2019-05-23 Evonik Röhm Gmbh Procédé de préparation d'une capsule à coque dure revêtue
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
US20200101085A1 (en) * 2018-09-28 2020-04-02 Joel Studin Transpore delivery of drugs and uses thereof
KR20220008271A (ko) * 2019-05-15 2022-01-20 에보닉 오퍼레이션스 게엠베하 캡슐 충전 기계를 사용한 셀룰로오스 또는 전분을 기반으로 하는 코팅을 갖는 충전된 경질 쉘 캡슐의 제조 방법
EP3968969A1 (fr) * 2019-05-15 2022-03-23 Evonik Operations GmbH Procédé de remplissage de capsules à enveloppe dure à revêtements de copolymères de (méth)acrylate avec une machine de remplissage de capsules
AU2020329775A1 (en) * 2019-08-09 2022-02-24 Tesorx Pharma, Llc Proliposomal testosterone undecanoate formulations
CN110747271B (zh) * 2019-12-02 2023-07-18 延边大学 关于pci术后血管损伤-再狭窄程度的标记物
JP6945874B2 (ja) * 2019-12-24 2021-10-06 一般財団法人バイオダイナミックス研究所 経口投与用医薬組成物
CN111840240A (zh) * 2020-05-29 2020-10-30 仁和堂药业有限公司 一种非那雄胺制剂及其应用
CN112121003B (zh) * 2020-09-29 2022-02-01 江苏集萃新型药物制剂技术研究所有限公司 缓释制剂载药材料及其组合物、缓释制剂及其制备方法
WO2022245650A1 (fr) * 2021-05-19 2022-11-24 Alberto Paz Compositions administrées par voie orale pour le traitement du cancer
CN114668719B (zh) * 2022-02-21 2023-06-16 广东食品药品职业学院 双氢睾酮混悬剂与双氢睾酮冻干粉及其制备方法
TW202417004A (zh) * 2022-09-16 2024-05-01 大陸商長春金賽藥業有限責任公司 類固醇激素磷脂組合物及其製備方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5002936A (en) 1985-04-12 1991-03-26 Seymour Lieberman Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
KR900004323A (ko) 1988-09-29 1990-04-12 후쿠하라 요시하루 유화 조성물
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US20040175417A1 (en) 1990-10-19 2004-09-09 Gilead Sciences, Inc. Amphotericin B liposome preparation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP3017906B2 (ja) 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
WO2002051426A2 (fr) 2000-12-22 2002-07-04 A Glenn Braswell Compositions et methodes permettant de traiter des dysfonctions sexuelles, d'ameliorer l'activite sexuelle et d'augmenter les niveaux de testosterone, et d'ameliorer la force et la masse musculaires
US6534080B2 (en) 2001-02-12 2003-03-18 Super Gen, Inc. Method for administering camptothecins via injection of pharmaceutical composition comprising coated particles of a camptothecin
US8658202B2 (en) * 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US20040115226A1 (en) 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
US20070053918A1 (en) 2003-05-12 2007-03-08 Novosom Ag Injectable depots consisting of liposomal aggregates for the delivery of active substances
ES2366646T3 (es) 2003-11-05 2011-10-24 Elan Pharma International Limited Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
WO2006012502A2 (fr) 2004-07-23 2006-02-02 Rigel Pharmaceuticals, Inc. Preparation d'agents therapeutiques a petites molecules insolubles dans des excipients lipidiques
WO2006062506A1 (fr) * 2004-12-03 2006-06-15 Enzrel, Inc. Administration de composes antioxydants ou anti-inflammatoires au moyen d'un medicament liposomal enrobe de chitosane
EP1959961A2 (fr) 2005-12-06 2008-08-27 Rigel Pharmaceuticals, Inc. Formulation d'agents thérapeutiques à base de petites molécules insolubles dans des supports lipidiques
US20070154403A1 (en) 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
WO2007117469A2 (fr) 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions de complexes protéine-lipide moins immunogéniques et à circulation prolongée
EP2146692A1 (fr) * 2007-03-19 2010-01-27 Fresenius Kabi Oncology Limited Compositions proliposomales et liposomales
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JP2013540827A (ja) * 2010-10-29 2013-11-07 ウエスタン ユニバーシティ オブ ヘルス サイエンシズ 三種混合製剤
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2013026002A1 (fr) 2011-08-18 2013-02-21 Monosol Rx, Llc Systèmes d'administration d'hormone stéroïde et procédés de préparation de ceux-ci

Also Published As

Publication number Publication date
EP2846781A2 (fr) 2015-03-18
MX367123B (es) 2019-08-06
US20150157572A1 (en) 2015-06-11
HK1211499A1 (en) 2016-05-27
MY175305A (en) 2020-06-18
JP2017061552A (ja) 2017-03-30
TW201350140A (zh) 2013-12-16
PE20150203A1 (es) 2015-02-01
ZA201408996B (en) 2017-08-30
CN104780914B (zh) 2018-02-09
US9844557B2 (en) 2017-12-19
AU2013259509A1 (en) 2015-01-15
CR20140561A (es) 2015-02-12
HK1255929A1 (zh) 2019-09-06
EA028809B1 (ru) 2018-01-31
HK1210409A1 (en) 2016-04-22
JP6055088B2 (ja) 2016-12-27
TN2014000467A1 (en) 2016-03-30
KR20150032939A (ko) 2015-03-31
CO7240373A2 (es) 2015-04-17
US20180303850A1 (en) 2018-10-25
JP2018021062A (ja) 2018-02-08
EA201492047A1 (ru) 2015-05-29
AR091006A1 (es) 2014-12-30
CN104780914A (zh) 2015-07-15
US9623033B2 (en) 2017-04-18
AP2014008099A0 (en) 2014-12-31
MX2014013450A (es) 2015-05-11
PH12014502498A1 (en) 2014-12-22
CL2014003034A1 (es) 2015-07-03
US20170065614A1 (en) 2017-03-09
WO2013170012A2 (fr) 2013-11-14
JP6368020B2 (ja) 2018-08-01
US8957053B2 (en) 2015-02-17
AU2017272249B2 (en) 2019-01-31
AU2013259509B2 (en) 2017-09-07
NZ721900A (en) 2018-01-26
JP6208842B2 (ja) 2017-10-04
TWI664982B (zh) 2019-07-11
IL235464B (en) 2019-09-26
MA37610B1 (fr) 2017-07-31
US20140112986A1 (en) 2014-04-24
EP2846781A4 (fr) 2016-03-30
EA201791738A1 (ru) 2018-03-30
ECSP14030572A (es) 2015-11-30
CN108096192A (zh) 2018-06-01
IN2014DN10383A (fr) 2015-08-14
DOP2015000026A (es) 2015-06-15
WO2013170012A3 (fr) 2015-06-04
JP2015520751A (ja) 2015-07-23
CA2872779A1 (fr) 2013-11-14
US20160375036A1 (en) 2016-12-29
UA115058C2 (uk) 2017-09-11
IL235464A0 (en) 2014-12-31
NZ702634A (en) 2016-09-30
BR112014027942A2 (pt) 2017-06-27
SG10201702240TA (en) 2017-05-30
US9445995B2 (en) 2016-09-20
TW201831169A (zh) 2018-09-01
GEP201706754B (en) 2017-10-25
AU2017272249A1 (en) 2017-12-21
ZA201509340B (en) 2018-05-30
SG11201407349UA (en) 2014-12-30
EP2846781B1 (fr) 2019-10-30
TWI614035B (zh) 2018-02-11

Similar Documents

Publication Publication Date Title
MA37610A1 (fr) Formulations de testostérone proliposomales
MX2018013668A (es) Inhibidores de virus de hapatitis c.
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
EP3904502A3 (fr) Compositions et procédés
MX2013011655A (es) Forma de dosis unitaria para administracion oral.
NZ712350A (en) Abiraterone acetate formulation
MX355036B (es) Vacunas combinadas de nanovehículos sintéticos.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
EP2544667A4 (fr) Compositions pharmaceutiques entériques résistantes aux alcools
EP2747563A4 (fr) Compositions et leurs procédés pour une administration orale de médicaments
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
TN2015000135A1 (en) Modified release formulations for oprozomib
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
SG10201901391RA (en) Induction of il-12 using immunotherapy
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
IN2013MU01177A (fr)
MX2023003000A (es) Formulaciones de liberacion modificada de viloxacina.
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
EP3065705A4 (fr) Compositions et procédés d'administration d'un enzyme dans les voies respiratoires d'un sujet
MY181226A (en) Formulation of metaxalone
JO3810B1 (ar) صيغ التستوستيرون الشحمية المساندة
MX2015013279A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
MX2016004445A (es) Formulacion en polvo de triflusal estable para la administracion oral y metodo de preparacion de esta.